Zhongzhi Pharmaceutical Holdings Limited
HKEX:3737.HK
0.92 (HKD) • At close November 12, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,049.812 | 1,825.935 | 1,746.5 | 1,603.876 | 1,342.182 | 1,142.15 | 944.634 | 730.472 | 688.036 | 595.565 | 482.805 |
| Cost of Revenue
| 831.669 | 758.586 | 685.152 | 612.787 | 507.944 | 438.729 | 383.253 | 331.034 | 312.958 | 275.29 | 243.43 |
| Gross Profit
| 1,218.143 | 1,067.349 | 1,061.348 | 991.089 | 834.238 | 703.421 | 561.381 | 399.438 | 375.078 | 320.275 | 239.375 |
| Gross Profit Ratio
| 0.594 | 0.585 | 0.608 | 0.618 | 0.622 | 0.616 | 0.594 | 0.547 | 0.545 | 0.538 | 0.496 |
| Reseach & Development Expenses
| 49.982 | 46.35 | 43.834 | 50.189 | 47.448 | 52.464 | 34.501 | 17.689 | 18.784 | 11.184 | 14.001 |
| General & Administrative Expenses
| 106.651 | 104.746 | 102.899 | 91.777 | 78.068 | 77.808 | 64.411 | 56.064 | 60.913 | 49.726 | 36.913 |
| Selling & Marketing Expenses
| 888.156 | 809.084 | 825.719 | 695.014 | 563.342 | 452.3 | 355.004 | 245.554 | 179.694 | 130.098 | 126.651 |
| SG&A
| 994.807 | 914.567 | 932.136 | 790.576 | 647.753 | 570.589 | 451.871 | 333.884 | 264.252 | 198.943 | 181.207 |
| Other Expenses
| 0 | 5.709 | 2.484 | -4.23 | 0.002 | 1.555 | -1.777 | -18.892 | 0 | 0 | 0 |
| Operating Expenses
| 1,019.26 | 934.14 | 996.672 | 828.727 | 682.566 | 611.293 | 477.139 | 338.977 | 275.114 | 205.361 | 191.855 |
| Operating Income
| 198.883 | 103.506 | 79.577 | 141.117 | 136.767 | 78.201 | 74.446 | 46.798 | 90.754 | 109.637 | 43.359 |
| Operating Income Ratio
| 0.097 | 0.057 | 0.046 | 0.088 | 0.102 | 0.068 | 0.079 | 0.064 | 0.132 | 0.184 | 0.09 |
| Total Other Income Expenses Net
| 8.698 | 24.219 | -23.565 | 16.898 | 19.174 | 23.622 | 15.429 | 22.361 | 10.437 | 5.173 | 3.444 |
| Income Before Tax
| 207.581 | 130.651 | 61.813 | 167.222 | 155.941 | 101.823 | 89.875 | 69.159 | 101.191 | 114.81 | 46.803 |
| Income Before Tax Ratio
| 0.101 | 0.072 | 0.035 | 0.104 | 0.116 | 0.089 | 0.095 | 0.095 | 0.147 | 0.193 | 0.097 |
| Income Tax Expense
| 43.447 | 23.736 | 9.447 | 28.603 | 41.247 | 16.754 | 19.819 | 15.287 | 20.652 | 28.122 | 9.165 |
| Net Income
| 162.775 | 106.387 | 52.128 | 138.532 | 114.694 | 85.069 | 70.056 | 53.872 | 80.539 | 86.688 | 37.638 |
| Net Income Ratio
| 0.079 | 0.058 | 0.03 | 0.086 | 0.085 | 0.074 | 0.074 | 0.074 | 0.117 | 0.146 | 0.078 |
| EPS
| 0.19 | 0.13 | 0.062 | 0.17 | 0.14 | 0.1 | 0.088 | 0.068 | 0.12 | 0.14 | 0 |
| EPS Diluted
| 0.19 | 0.13 | 0.06 | 0.17 | 0.14 | 0.1 | 0.087 | 0.067 | 0.12 | 0.14 | 0 |
| EBITDA
| 317.528 | 153.871 | 119.714 | 203.693 | 166.49 | 102.441 | 96.814 | 68.449 | 106.803 | 121.68 | 54.152 |
| EBITDA Ratio
| 0.155 | 0.084 | 0.069 | 0.127 | 0.124 | 0.09 | 0.102 | 0.094 | 0.155 | 0.204 | 0.112 |